Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Srimathi S. Srinivasan"'
Autor:
A. Hughes, Patricia McCoon, Stephen Fawell, Gayathri Bommakanti, Simon T. Barry, Deanna A. Mele, Larissa S. Carnevalli, Christopher Womack, Michael Collins, Nanhua Deng, Lukasz Magiera, Mingchao Xie, J. Carl Barrett, Richard Woessner, Srimathi S. Srinivasan, Deanna L. Russell, Shaun E Grosskurth, Corinne Reimer, Maneesh Singh, Minwei Ye, Theresa Proia, Matthew Griffin, Susan Cantin
Publikováno v:
Clinical Cancer Research. 26:6335-6349
Purpose: Danvatirsen is a therapeutic antisense oligonucleotide (ASO) that selectively targets STAT3 and has shown clinical activity in two phase I clinical studies. We interrogated the clinical mechanism of action using danvatirsen-treated patient s
Autor:
Deanna L. Russell, Gozde Kar, Grant Duclos, Peter Gathungu, Patricia McCoon, Minoo Rafati, Tim Slidel, J. Carl Barrett, David Whitston, Srimathi S. Srinivasan, Ben Sidders
Publikováno v:
Cancer Research. 81:390-390
Cell-type abundance GE signatures are useful for informing drug mechanism of action and may be useful in-patient selection for cancer immunotherapies. Recently, we validated natural killer cell- and dendritic cell-type specific expression signatures
Autor:
Theresa Proia, Srimathi S. Srinivasan, Yang Xu, Alexandra-Chloé Villani, Nanhua Deng, J. Carl Barrett, Patricia McCoon
Publikováno v:
Cancer Research. 79:3215-3215
Danvatirsen (AZD9150) is a therapeutic antisense oligonucleotide that selectively targets human STAT3, a ubiquitously expressed transcription factor and master regulator of immune suppression in the tumor microenvironment (TME). Danvatirsen has shown
Autor:
Mineva ND; Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA.; Adecto Pharmaceuticals, Inc., Boston, MA 02446, USA., Pianetti S; Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA.; Adecto Pharmaceuticals, Inc., Boston, MA 02446, USA., Das SG; Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA., Srinivasan S; Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA., Billiald NM; Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA., Sonenshein GE; Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA.; Adecto Pharmaceuticals, Inc., Boston, MA 02446, USA.
Publikováno v:
Pharmaceutics [Pharmaceutics] 2024 Apr 13; Vol. 16 (4). Date of Electronic Publication: 2024 Apr 13.
Autor:
Cooper A; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL., Tumuluru S; Committee on Cancer Biology, University of Chicago, Chicago, IL., Kissick K; Department of Pathology, University of Chicago, Chicago, IL., Venkataraman G; Department of Pathology, University of Chicago, Chicago, IL., Song JY; Department of Pathology, City of Hope, Duarte, CA., Lytle A; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC., Duns G; Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada., Yu J; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL., Kotlov N; BostonGene, Waltham, MA., Bagaev A; BostonGene, Waltham, MA., Hodkinson B; Oncology Translational Research, Janssen Research & Development, Spring House, PA., Srinivasan S; Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA., Smith SM; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL., Scott DW; Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada., Steidl C; Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada., Godfrey JK; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Kline J; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.; Committee on Cancer Biology, University of Chicago, Chicago, IL.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Feb 01; Vol. 42 (4), pp. 467-480. Date of Electronic Publication: 2023 Dec 11.
Autor:
Niemann CU; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: carsten.utoft.niemann@regionh.dk., Munir T; St James's Hospital, Leeds, UK., Moreno C; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Owen C; Tom Baker Cancer Centre, Calgary, AB, Canada., Follows GA; Addenbrookes Hospital, Cambridge, UK., Benjamini O; Sheba Medical Center, Ramat Gan, Israel., Janssens A; UZ Leuven Gasthuisberg, Leuven, Belgium., Levin MD; Albert Schweitzer Hospital, Dordrecht, Netherlands., Robak T; Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland., Simkovic M; 4th Department of Internal Medicine-Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic., Voloshin S; Russian Scientific and Research Institute of Hematology and Transfusiology, St Petersburg, Russia., Vorobyev V; SP Botkin Moscow City Clinical Hospital, Moscow, Russia., Yagci M; Gazi Universitesi Tip Fakultesi, Ankara, Türkiye., Ysebaert L; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France., Qi K; Janssen Research & Development, Titusville, NJ, USA., Qi Q; Janssen Research & Development, Raritan, NJ, USA., Sinet P; Janssen Research & Development, Bridgewater, NJ, USA., Parisi L; Janssen Research & Development, Raritan, NJ, USA., Srinivasan S; Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA, USA., Schuier N; Janssen Research & Development, Raritan, NJ, USA., Baeten K; Janssen Research & Development, Beerse, Belgium., Howes A; Janssen Research & Development, High Wycombe, UK., Caces DB; Janssen Research & Development, Raritan, NJ, USA., Kater AP; Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, Netherlands.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2023 Dec; Vol. 24 (12), pp. 1423-1433. Date of Electronic Publication: 2023 Nov 06.
Autor:
Moreno C; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Solman IG; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA., Tam CS; Department of Hematology, Alfred Hospital and Monash University, Melbourne, VIC, Australia., Grigg A; Austin Hospital, Heidelberg, VIC, Australia., Scarfò L; Division of Experimental Oncology, Università Vita Salute San Raffaele and Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy., Kipps TJ; Moores Cancer Center, University of California San Diego, La Jolla, CA., Srinivasan S; Janssen Research & Development, Lower Gwynedd Township, PA., Mali RS; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA., Zhou C; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA., Dean JP; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA., Szafer-Glusman E; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA., Choi M; University of California San Diego, La Jolla, CA.
Publikováno v:
Blood advances [Blood Adv] 2023 Sep 26; Vol. 7 (18), pp. 5294-5303.
Autor:
Munir T; St James's Hospital, Leeds, United Kingdom., Moreno C; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Research Leukaemia Research Institute, Barcelona, Spain., Owen C; Tom Baker Cancer Centre, Calgary, Canada., Follows G; Addenbrookes Hospital, Cambridge, United Kingdom., Benjamini O; Sheba Medical Center, Ramat Gan, Israel., Janssens A; UZ Leuven Gasthuisberg, Leuven, Belgium., Levin MD; Albert Schweitzer Hospital, Dordrecht, the Netherlands., Osterborg A; Karolinska University Hospital, Stockholm, Sweden., Robak T; Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland., Simkovic M; University Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Stevens D; Norton Cancer Institute, Louisville, KY., Voloshin S; Russian Scientific and Research Institute of Hematology and Transfusiology, St Petersburg, Russia., Vorobyev V; S.P. Botkin Moscow City Clinical Hospital, Moscow, Russia., Yagci M; Gazi Universitesi Tip Fakultesi, Ankara, Turkey., Ysebaert L; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France., Qi K; Janssen Research & Development, Titusville, NJ., Qi Q; Janssen Research & Development, Raritan, NJ., Parisi L; Janssen Research & Development, Raritan, NJ., Srinivasan S; Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA., Schuier N; Janssen Research & Development, Düsseldorf, Germany., Baeten K; Janssen Research & Development, Beerse, Belgium., Howes A; Janssen Research & Development, High Wycombe, United Kingdom., Caces DB; Janssen Research & Development, Raritan, NJ., Niemann CU; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark., Kater AP; Amsterdam Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jul 20; Vol. 41 (21), pp. 3689-3699. Date of Electronic Publication: 2023 Jun 06.
Autor:
Johnson PWM; Centre for Cancer Immunology, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Balasubramanian S; Oncology Translational Research, Janssen Research & Development, San Diego, CA., Hodkinson B; Oncology Translational Research, Janssen Research & Development, Spring House, PA., Shreeve SM; Clinical Oncology, Janssen Research & Development, San Diego, CA., Sun S; Oncology Translational Research, Janssen Research & Development, Spring House, PA., Srinivasan S; Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA., Steele AJ; Oncology Translational Research, Janssen Research & Development, Spring House, PA., Vermeulen J; Clinical Oncology, Janssen Research & Development, Leiden, The Netherlands., Sehn LH; British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver, BC, Canada., Wilson WH; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Publikováno v:
Blood advances [Blood Adv] 2023 May 23; Vol. 7 (10), pp. 2008-2017.
Autor:
Doshi AS; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Cantin S; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Hernandez M; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Srinivasan S; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Tentarelli S; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Griffin M; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Wang Y; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Pop-Damkov P; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts., Prickett LB; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Kankkonen C; Discovery Sciences, R&D, AstraZeneca, Mölndal, Sweden., Shen M; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Martin MS; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Wu S; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Castaldi MP; Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts., Ghadially H; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Varnes J; Global Portfolio and Project Management, Waltham, Massachusetts., Gales S; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Henry D; Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Toxicology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Hoover C; Safety Pathology, Oncology R&D, AstraZeneca, Boston, Massachusetts., Mele DA; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Simpson I; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gangl ET; Drug Metabolism and Pharmacokinetics, Oncology R&D, Waltham, Massachusetts., Mlynarski SN; Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Finlay MRV; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Drew L; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fawell SE; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Shao W; Projects, Oncology R&D, AstraZeneca, Boston, Massachusetts., Schuller AG; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2023 May 04; Vol. 22 (5), pp. 630-645.